The abstract is read at the publisher; the summary is JClub's.
FKBP10 is strikingly elevated in breast cancer tissues and is linked to enhanced homologous recombination, driving broad resistance to cisplatin, ionizing radiation, and PARP inhibitors.
- Why it matters: Refractory, therapy-resistant breast cancer—especially molecular subtypes without actionable targets—needs new mechanisms and druggable vulnerabilities to improve responses to DNA-damaging treatments.
- What they did: The study mapped FKBP10’s role in vitro and in vivo, showing it binds RAD51 through a proline 22-containing motif to block HSC70 recognition and protect RAD51 from CMA-dependent degradation, with ATF6-mediated ER stress further stabilizing RAD51. It also used selumetinib to repress FKBP10 via MEK/ERK/ELK1 signaling.
- The result: Selumetinib robustly sensitized multiple preclinical breast cancer models to chemoradiotherapy and PARP inhibition, implying FKBP10 is a tractable therapeutic target for resistant subsets.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.